NCT07574242Completed
Effect of vitk2 on Atopic Dermatitis Pediatrics Patients
Evaluation of the Effect of Vitamin K2 on the Clinical Outcome of Pediatric Patients With Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
investigate the effectiveness and safety of adding vitamin K2 at a dose of 45 mg/day for 12 weeks to conventional therapy for paediatric patients with moderate to severe atopic dermatitis according to SCORAD score
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 6 Jan 2026
- Start date
- Aug 2024
- Primary completion date
- May 2025
- Lead sponsor
- October 6 University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07574242
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From Aug 2024 to the primary completion date, May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- other cutaneous allergic diseases (urticaria, angioedema, anaphylaxis, contact dermatitis).
- primary immunodeficiency (PID) with cutaneous allergic manifestations.
Who the study is looking for
- patients aged 6-12 years
- moderate to severe AD according to SCORAD score
Age in the registry: 6 years to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| October 6 University Coordinator of this site? Confirm its status | Giza | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.